Similar Outcomes of Three Different Treatment Regimens Reported in Multiple Myeloma
the Cancer Therapy Advisor take:
Three salvage infusional chemotherapy regimens produced similar responses, survival, and adverse events in patients with multiple myeloma, according to an article published online in the journal Cancer.
In a single-institution study, three salvage chemotherapy regimens were compared among 107 patients with recurrent multiple myeloma who were treated using one of three salvage chemotherapy regimens.
Fifty-two patients received dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) cohort; 22 received bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide (VTD-PACE) treatment group; and 33 patients received cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD).
There were some differences between groups. For example, patients treated with CVAD had a higher baseline creatinine (P<0.001) and those treated with VTD-PACE had greater prior use of infusional chemotherapy (P<0.001).
Regarding patient response, no significant differences were reported among the three groups (55% overall; P=0.18).
Similarly, no significantly different outcomes were reported for survival among the three groups: overall median progression-free survival of 4.5 months (95% CI: 3.6, 5.5 months; P=0.8) and a median overall survival of 8.5 months (95% CI: 6.1, 11 months; P=0.8). DCEP, VTD-PACE, and CVAD demonstrated similar clinical adverse events; however, it was noted that DCEP was suggested as having fewer events.
Sixty-two percent of patients with the intent to transplant were successfully bridged to transplant without further therapy (P=0.9).
Furthermore, the intent-to-transplant population had greater response outcomes (OR, 3.40; P=0.01), superior progression-free survival (HR, 0.28; P<0.001), and increased overall survival (HR, 0.19; P<0.001).
Three salvage infusional chemotherapy regimens produced similar responses, survival, and adverse events in patients with multiple myeloma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy